Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects

This study has been terminated.
(Terminated due to unfavorable human pharmacokinetic properties)
Information provided by:
GlaxoSmithKline Identifier:
First received: April 7, 2011
Last updated: December 1, 2011
Last verified: December 2011

GSK2485852 is a Hepatitis C NS5B site IV non-nucleoside polymerase inhibitor being developed for the treatment of chronic HCV infection. HBI115040 is the first administration of GSK2485852 in humans to establish the initial safety, tolerability, pharmacokinetic, and antiviral profile. The study design is a fusion of single and repeat dosing cohorts in HCV infected subjects to evaluate the safety, pharmacokinetics, and antiviral activity of GSK2485852.

HBI115040 describes a Phase I, randomized, double-blind, placebo-controlled, dose escalation fusion study to determine the safety, tolerability, pharmacokinetic, and antiviral profile of GSK2485852 in single doses (Part 1), repeat doses (Part 2), and ritonavir co-administration (Part 3) in chronically infected HCV subjects. The study will also explore the effect of a moderate (30%) fat meal on pharmacokinetic endpoints in HCV subjects in Part 1.

Condition Intervention Phase
Hepatitis C
Drug: GSK2485852 70 mg
Drug: GSK2485852 420 mg
Drug: placebo
Drug: GSK2485852 630 mg
Drug: GSK2485852 70 mg + Ritonavir 100mg
Drug: GSK2485852 210 mg + Ritonavir 100mg
Drug: GSK2485852 210 mg +Ritonavir 100mg
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Safety parameters: adverse events; telemetry; absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs (blood pressure, heart rate), and electrocardiogram (ECG) parameters [ Time Frame: up to 7 days ] [ Designated as safety issue: Yes ]
  • GSK2485852 PK parameters following single dose administration: AUC(0-inf), AUC(0-t), AUC(0-24), Cmax, tmax, C24, t1/2, tlag, and CL/F [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • GSK2485852 PK parameters following repeat dose administration: AUC(0-τ), Cτ, Cmax, tmax, t1/2, and CL/F [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
  • HCV RNA viral load reduction from baseline [ Time Frame: 24 to 72 h ] [ Designated as safety issue: No ]
  • HCV RNA change from baseline to nadir [ Time Frame: up to 72 h ] [ Designated as safety issue: No ]
  • Time course of HCV viral load at baseline, during dosing with GSK2485852, and > or = 14 days after GSK2485852 dosing [ Time Frame: up to 14 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • GSK2485852 PK parameters: AUC(0-24), Cmax, tmax and tlag following a single dose with and without moderate fat/calorie meal. [ Time Frame: 24 h ] [ Designated as safety issue: No ]
  • GSK2485852 accumulation ratio (R) [ Time Frame: 72 h ] [ Designated as safety issue: No ]
  • GSK2485852 time invariance in non-food cohorts [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
  • GSK2485852 dose proportionality after single or repeat dosing in non-food cohorts [ Time Frame: up to 72 h ] [ Designated as safety issue: No ]

Enrollment: 27
Study Start Date: January 2011
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part 1: Single dose escalation
GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food
Drug: GSK2485852 70 mg
single dose
Drug: GSK2485852 420 mg
single dose
Drug: placebo
single dose
Drug: GSK2485852 70 mg + Ritonavir 100mg
single dose, day 1
Experimental: Part 2: Repeat dose escalation
GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID
Drug: placebo
Repeat dose, once daily for 3 days
Drug: GSK2485852 420 mg
Repeat dose, twice daily for 3 days
Drug: GSK2485852 420 mg
Repeat dose, TIDfor 3 days
Drug: GSK2485852 630 mg
Repeat dose, twice daily for 3 days
Drug: GSK2485852 210 mg + Ritonavir 100mg
single dose, day 1
Experimental: Part 3: GSK2485852 + Ritonavir
GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;
Drug: GSK2485852 210 mg +Ritonavir 100mg
single dose daily for 3 days


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A subject will be eligible for inclusion in this study only if all of the following criteria apply: Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring (i.e., ECG), including no cardiac, pulmonary, hepatic, biliary, gastrointestinal, or renal disorders, or cancer within the past 5 years.
  • Males or females between 18 and 65 years of age inclusive, at the time of signing the informed consent.
  • A female subject is eligible to participate if she is of non-childbearing potential.
  • Body weight > or = 50 kg (110 lbs.) for men and > or = 45 kg (99 lbs.) for women and BMI between 18.5-35.0 kg/m2 inclusive will be allowed.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • AST, ALT, and alkaline phosphatase <3.0xULN and bilirubin <1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Average QTcB or QTcF < 450 msec; or QTcB or QTcF < 480 msec in subjects with Bundle Branch Block.
  • Treatment naive chronically infected HCV subjects, defined as infection for >6 months and no prior HCV therapy, with an HCV RNA viral load of greater than 100,000 IU/mL and HCV genotype 1a or 1b. HCV subjects with mixed genotypes are not eligible for the study.
  • Positive for HCV RNA and anti-HCV antibody at the time of screening AND positive for anti-HCV antibody, HCV RNA, or an HCV genotype at least 6 months before screening; OR Positive for HCV RNA and anti-HCV antibody at the time of screening AND liver biopsy within three years prior to screening indicating the absence of cirrhosis.

Exclusion Criteria:

  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated.
  • A positive pre-study Hepatitis B surface antigen or HIV antibody within 3 months of screening.
  • A positive pre-study drug/alcohol screen.
  • History of regular alcohol consumption within 6 months of the study.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). Exposure to more than four new investigational products within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication,
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Holter monitoring shows one or more of the following: Any symptomatic arrhythmia (except isolated extra systoles); Sustained cardiac arrhythmias (such as atrial fibrillation or flutter, SVT (>10 consecutive beats)); Sustained tachycardia >150 beats per minute; Non-sustained or sustained ventricular tachycardia (defined as >3 consecutive ventricular ectopic beats); Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher in an awake subject], WPW syndrome, other pre-excitation syndromes); Symptomatic sinus pause or sinus pause >3 seconds - unless patient is straining, vomiting, or having some other type of hypervagal response; 300 or more supraventricular ectopic beats in 24 hours; 250 or more ventricular ectopic beats in 24 hours; Ischemia, diagnosed by a sequence of ECG changes that include flat or downsloping ST-segment depression >0.1 mV, with a gradual onset and offset that lasts for a minimum period of 1 minute. Each episode of ischemia must be separated by a minimum duration of at least 1 minute, during which the ST segment returns back to baseline (1x1x1 rule).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01332552

United States, California
GSK Investigational Site
Anaheim, California, United States, 92801
United States, Florida
GSK Investigational Site
Orlando, Florida, United States, 32803
United States, Kansas
GSK Investigational Site
Lenexa, Kansas, United States, 66219
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
United States, New Jersey
GSK Investigational Site
Willingboro, New Jersey, United States, 08046
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT01332552     History of Changes
Other Study ID Numbers: 115040 
Study First Received: April 7, 2011
Last Updated: December 1, 2011
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by GlaxoSmithKline:
First administration to human
antiviral activity
hepatitis C

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Antiviral Agents
Anti-Infective Agents
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on October 27, 2016